- Options Smell 'Blood' on Infosys
- Art Cashin: Traders Weigh Obama Policy Changes
- S&P's Stovall: Pullback to 810 is Likely
- What Options Say About Transports Now
- Art Cashin: Stimulus Package Was a 'Hoax'
- Healthcare Gains and Other Signs of the Bear
- What's The Biggest Options Trade Today?
- Santelli Debate: Are Banks On the Right Track?
- Art Cashin: Dow Trapped in 17-Year Cycle
- Barclays Adjusts Its Oil Stock Price Targets
|
CNBC'S MOST SHARED
- Apartment Vacancy Rate Hits 22-Year High
- Investing in Tech Now
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett: Economy Needs Another Dose of Viagra
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- New Jobless Claims Plunge; Continuing Claims Hit Record
- Citigroup Replaces CFO, Shakes Up Top Management
- Cramer?s Outrage
- Preparing for Retirement
- Microsoft Plays a Game of Bing Pong
- July 10th in Market History
- Microsoft Plays a Game of Bing Pong
- Options Smell 'Blood' on Infosys
- Christmas in July: Consumers To Out-Scrooge Scrooge
- GM's Second Chance
- Art Cashin: Traders Weigh Obama Policy Changes
- Warren Buffett: Economy Needs Another Dose of Viagra
- Commercial Real Estate: 'Ticking Time Bomb'
- Will LeBron Dunk Tape Ever Be Released?
- Chevron Says Q2 Hit by US Refining, Weak Dollar
- Stimulus Critics Put Obama, Democrats on Defensive
- Warren Buffett: Consumer Sales Remain 'Very, Very Soft'
- Don’t Get Burned By Hot Emerging Markets
- Busch: Chinese Bank Announces Bombshell
- Lenny Dykstra: 'Bank Fraud' Led to Bankruptcy
- Christmas in July: Consumers to Out-Scrooge Scrooge
- Software Giants Rush to Cash In on Carbon-Trading
- Video Game Makers Finding Gold in Old Titles
RSS FEED
Text Size 
Will Muggia likes biotech. Muggia's Touchstone Mid-Cap Growth Fund is up an average of 14.9 percent annually over the last three years -- and even this year, it's up 1.8 percent. So what are the 4-star portfolio manager's picks?
Recommendations:
Muggia likes Celgene [CELG
Loading...
()
], "one of the fastest-growing biotechnology companies in the world today. He expects the firm to have 40 percent earnings growth.
He praises Elan Pharmaceuticals [ELAN
Loading...
()
] for its auto-immune and Alzheimer's medicines. He says the latter illness has barely begun to be addressed medically, with plenty of potential left.
CNBC.com Web Exclusive:
(Not found on TV)
For CNBC.com readers, Muggia also recommends Chesapeake Energy [CHK
Loading...
()
].
Disclosures:
Muggia personally owns both Celgene and Elan, and the stocks are the largest holdings in his fund.
Data is a real-time snapshot *Data is delayed at least 15 minutes